Matinas Biopharma Holdings, Inc. (AMEX:MTNB) summarized second quarter financial results before market open today.
The company revealed loss for the second quarter of $ 3.61 million or $ 0.03 per share, compared to loss of $ 3.58 million or $ 0.04 per share for the year-ago quarter., while Street analysts expected loss of $ 0.03 per share
MTNB posted revenue for second quarter to $ 0.09 million from $ 0.09 million in the same quarter last year, where as According to street consensus, revenue of $ 0.02 million was expected for the second quarter
Analysts estimates are from Thomson Reuters, exclude one time gain or loss.
Jerome D. Jabbour, Chief Executive Officer, commented, We have designed a pathway to approval intended to yield clinical data we believe could differentiate MAT9001 from the leading approved prescription-only omega-3 products and take advantage of exciting new developments within this class of drugs to potentially treat millions of patients.